The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The dopamine transporter: A crucial component regulating dopamine transmission
Abstract
The dopamine system is implicated in the control of locomotion, cognition, and endocrine function, The relative contribution of the various dopamine‐related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this “genetic defect.” leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter‐acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Cited by
Benamer, H. T. S., Patterson, J., Grosset, D. G., Booij, J., de Bruin, K., van Royen, E., Speelman, J. D., Horstink, M. H. I. M., Sips, H. J. W. A., Dierckx, R. A., et al. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-v · Cited by 707
The Family of Na+/Cl− Neurotransmitter Transporters
Nelson, N. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71051785.x · Cited by 358
Lewis, D. A., Melchitzky, D. S., Sesack, S. R., Whitehead, R. E., Auh, S., & Sampson, A. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1092 · Cited by 352
Striatal dopamine transporters and cognitive functioning in healthy men and women
Mozley, L. H., Gur, R. C., Mozley, P. D., & Gur, R. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1492 · Cited by 314
Laviola, G., Hannan, A. J., Macrì, S., Solinas, M., & Jaber, M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.001 · Cited by 300
Self-citationHoffman, B. J., Hansson, S. R., Mezey, É., & Palkovits, M. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0168 · Cited by 279
Gene–gene interaction associated with neural reward sensitivity
Yacubian, J., Sommer, T., Schroeder, K., Gläscher, J., Kalisch, R., Leuenberger, B., Braus, D. F., & Büchel, C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702029104 · Cited by 241
Krugel, L. K., Biele, G., Mohr, P. N. C., Li, S.-C., & Heekeren, H. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905191106 · Cited by 229
“, DA transporter reuptake (13, 14, 17, 18) or DA activity regulation at the postsynaptic site (6, 7, 41)] that determine dopaminergic activity.”
BackgroundAdiposity signals and food reward: expanding the CNS roles of insulin and leptin
Figlewicz, D. P. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00602.2002 · Cited by 221
Schott, B. H., Seidenbecher, C. I., Fenker, D. B., Lauer, C. J., Bunzeck, N., Bernstein, H.-G., Tischmeyer, W., Gundelfinger, E. D., Heinze, H.-J., & Düzel, E. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3463-05.2006 · Cited by 214
Solinas, M., Thiriet, N., Rawas, R. E., Lardeux, V., & Jaber, M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.51 · Cited by 175
“Cocaine elevates dopamine levels by binding to the dopamine membrane transporter (DAT) and preventing dopamine reuptake by presynaptic terminals (Jaber et al, 1997) and these dopamine elevations in the NAc are considered central in the mediation of the reinforcing effects of psychostimulants (Di…”
Self-citationvan der Wee, N. J., Stevens, H., Hardeman, J. A., Mandl, R. C., Denys, D. A., van Megen, H. J., Kahn, R. S., & Westenberg, H. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.12.2201 · Cited by 149
“Higher transporter density may result from a higher homeostatic tone of the dopaminergic system, with lower densities of D1 and D2 receptors (33, 34).”
BackgroundN‐Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease
Monti, D. A., Zabrecky, G., Kremens, D., Liang, T., Wintering, N. A., Bazzan, A. J., Zhong, L., Bowens, B. K., Chervoneva, I., Intenzo, C., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1548 · Cited by 121
Amsterdam, J. D., & Newberg, A. B. (2007) · Neuropsychobiology · doi:10.1159/000106476 · Cited by 84
Chang, T. T., Yeh, T. L., Chiu, N. T., Chen, P. S., Huang, H. Y., Yang, Y. K., Lee, I. H., & Lu, R. B. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00771.x · Cited by 63
Correlation of Parkinson's disease severity and duration with123I-FP-CIT SPECT striatal uptake
Benamer, H. T. S., Patterson, J., Wyper, D. J., Hadley, D. M., Macphee, G. J. A., & Grosset, D. G. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v
Metadata
- Authors
- Jaber, M., Jones, S., Giros, B., & Caron, M. G.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 1997-09
- Volume
- 12
- Issue
- 5
- Pages
- 629-633
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2147600591
- Cited by
- 232
- References
- 1
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.